Oxybutynin Chloride

Common brands: Oxybutynin Chloride Extended Release, Vitamin D, Neurontin, Acid Reducer, Gralise

Top reporter: Lannett Company, Inc.

Nonsteroidal Anti-inflammatory Drug [EPC]Provitamin D2 Compound [EPC]Benzodiazepine [EPC]Corticosteroid [EPC]Platelet Aggregation Inhibitor [EPC]
8,547
Total Reports
3,477
Serious Reports
537
Death Reports
30
Reported Reactions
Death Report Ratio: High (6.28%)

Patient Demographics

Male
2,330
Female
5,673

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Oxybutynin Chloride.

# Reaction Reports % of Total
1 FATIGUE 713
6.6%
2 DRUG INEFFECTIVE 684
6.3%
3 NAUSEA 586
5.4%
4 FALL 574
5.3%
5 HEADACHE 547
5.0%
6 DIARRHOEA 499
4.6%
7 PAIN 477
4.4%
8 URINARY TRACT INFECTION 445
4.1%
9 DIZZINESS 423
3.9%
10 CONSTIPATION 400
3.7%
11 ASTHENIA 386
3.6%
12 OFF LABEL USE 368
3.4%
13 WEIGHT DECREASED 360
3.3%
14 GAIT DISTURBANCE 347
3.2%
15 PRODUCT DOSE OMISSION ISSUE 330
3.0%
16 MALAISE 324
3.0%
17 DYSPNOEA 310
2.9%
18 PNEUMONIA 276
2.5%
19 PYREXIA 272
2.5%
20 VOMITING 269
2.5%
21 DEATH 266
2.4%
22 ARTHRALGIA 257
2.4%
23 PRURITUS 237
2.2%
24 COUGH 233
2.1%
25 ABDOMINAL PAIN 221
2.0%
26 ANAEMIA 219
2.0%
27 BACK PAIN 219
2.0%
28 DEPRESSION 213
2.0%
29 PAIN IN EXTREMITY 205
1.9%
30 INSOMNIA 204
1.9%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.